Wells Fargo & Company MN Has $3.46 Million Holdings in Momenta Pharmaceuticals, Inc. (MNTA)

Wells Fargo & Company MN raised its holdings in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 13.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 247,949 shares of the biotechnology company’s stock after acquiring an additional 28,429 shares during the period. Wells Fargo & Company MN’s holdings in Momenta Pharmaceuticals were worth $3,458,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Bank of New York Mellon Corp raised its holdings in Momenta Pharmaceuticals by 6.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 897,784 shares of the biotechnology company’s stock valued at $16,609,000 after acquiring an additional 56,748 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in Momenta Pharmaceuticals by 6.4% in the 3rd quarter. Ameriprise Financial Inc. now owns 736,068 shares of the biotechnology company’s stock valued at $13,617,000 after acquiring an additional 44,290 shares during the last quarter. Schwab Charles Investment Management Inc. grew its stake in shares of Momenta Pharmaceuticals by 4.5% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 409,519 shares of the biotechnology company’s stock valued at $5,713,000 after buying an additional 17,727 shares during the period. Sectoral Asset Management Inc grew its stake in shares of Momenta Pharmaceuticals by 24.4% during the 3rd quarter. Sectoral Asset Management Inc now owns 372,499 shares of the biotechnology company’s stock valued at $6,891,000 after buying an additional 73,099 shares during the period. Finally, Legal & General Group Plc grew its stake in shares of Momenta Pharmaceuticals by 21.4% during the 3rd quarter. Legal & General Group Plc now owns 154,060 shares of the biotechnology company’s stock valued at $2,851,000 after buying an additional 27,173 shares during the period. Institutional investors own 97.64% of the company’s stock.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ MNTA opened at $17.50 on Friday. Momenta Pharmaceuticals, Inc. has a 52-week low of $11.85 and a 52-week high of $19.25.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $0.18 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.12. Momenta Pharmaceuticals had a negative net margin of 63.43% and a negative return on equity of 23.62%. The firm had revenue of $64.60 million during the quarter, compared to analysts’ expectations of $66.59 million. During the same period in the prior year, the company earned $0.60 EPS. The firm’s revenue was up 88.9% on a year-over-year basis. sell-side analysts forecast that Momenta Pharmaceuticals, Inc. will post -1.27 earnings per share for the current fiscal year.

In related news, Director Elizabeth Stoner sold 16,264 shares of the company’s stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $18.00, for a total transaction of $292,752.00. Following the completion of the sale, the director now directly owns 32,440 shares of the company’s stock, valued at approximately $583,920. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Bruce Leicher sold 1,861 shares of the company’s stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $16.00, for a total transaction of $29,776.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 70,836 shares of company stock valued at $1,158,448. 4.40% of the stock is owned by corporate insiders.

Several analysts have recently issued reports on MNTA shares. Zacks Investment Research raised shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. ValuEngine raised shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 23rd. BidaskClub cut shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, March 27th. Finally, Stifel Nicolaus reissued a “hold” rating and set a $18.00 price objective on shares of Momenta Pharmaceuticals in a research note on Tuesday, January 30th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company. Momenta Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $15.33.

TRADEMARK VIOLATION NOTICE: This piece was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/3337952/wells-fargo-company-mn-has-3-46-million-holdings-in-momenta-pharmaceuticals-inc-mnta.html.

Momenta Pharmaceuticals Profile

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE.

Want to see what other hedge funds are holding MNTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA).

Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Todd Michael Morgan Sells 12,600 Shares of Fiera Capital  Stock
Todd Michael Morgan Sells 12,600 Shares of Fiera Capital Stock
Travelport  Hits New 52-Week High and Low at $17.25
Travelport Hits New 52-Week High and Low at $17.25
Progressive  Sets New 1-Year High and Low Following Better-Than-Expected Earnings
Progressive Sets New 1-Year High and Low Following Better-Than-Expected Earnings
Harris  Rating Lowered to Sell at Zacks Investment Research
Harris Rating Lowered to Sell at Zacks Investment Research
Plantronics  Given Daily News Sentiment Rating of 0.19
Plantronics Given Daily News Sentiment Rating of 0.19
Genuine Parts  Earns Neutral Rating from Analysts at Guggenheim
Genuine Parts Earns Neutral Rating from Analysts at Guggenheim


Leave a Reply

© 2006-2018 Ticker Report. Google+.